• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

    5/9/24 7:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email

    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK.

    "Our mission to unlock the broad potential of RNA medicines requires us to combine the capabilities of our best-in-class oligonucleotide platform with novel drug targets informed by human genetics. Dr. Ingelsson brings to Wave deep expertise in genetics and drug discovery, as well as substantial experience in metabolic diseases. He will leverage his experience to accelerate identification of new genetic insights and rapidly translate those insights into RNA medicines at Wave, including with our wholly owned INHBE program for obesity," said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "I am excited to welcome Dr. Ingelsson to our leadership team and look forward to his contributions, which will shape the future of our sustainable, diverse and impactful therapeutic pipeline across multiple modalities, including RNA editing and siRNA."

    While at GSK, Dr. Ingelsson led a team focused on a large-scale, industrialized approach to target discovery and validation, bringing together functional genomics, chemical biology, structural biology, protein and cellular sciences to drive drug discovery and development. His organization worked across all therapeutic areas at GSK.

    Previously, Dr. Ingelsson was the SVP of Genomic Sciences at GSK, an organization with world-leading skills and capabilities in human genetics, computational biology, omics technologies and gene editing, responsible for harnessing the latest methods and technologies in genomics to discover and validate novel drug targets, and to drive more successful development of the next generation of medicines. Before joining GSK, Dr. Ingelsson was Professor of Medicine at Stanford University. His lab used human genetics and functional genomics to discover novel biology and drug targets related to insulin resistance and related conditions, such as obesity, MASH, and cardiovascular disease. His work combined large-scale human genetics studies with in-depth pre-clinical validation work and an emphasis on cardiometabolic diseases.

    Dr. Ingelsson obtained his MD and PhD at Uppsala University, Sweden. After clinical internship and residency, he undertook postdoctoral research at the Framingham Heart Study before joining the faculty at Karolinska Institutet (Stockholm, Sweden), where he was appointed Professor of Cardiovascular Epidemiology. He was also Professor of Molecular Epidemiology at Uppsala University and was a visiting professor at Oxford University. He has published over 400 peer-reviewed original articles and has an h-index of 145.  

    "Having gotten to know Wave through its collaboration with GSK, I have seen firsthand the enormous potential of its world-leading RNA therapeutics platform and its people to rapidly translate genetic insights into novel medicines," said Dr. Ingelsson. "I am thrilled to join Wave during this incredibly exciting time with multiple near-term clinical data readouts approaching and a rapidly advancing INHBE program that exemplifies Wave's ability to execute ahead of plan and accelerate a program with incredible potential to disrupt the obesity space and deliver value to patients and shareholders. Wave has built an extraordinary, innovative, and agile discovery team and I look forward to leading this talented organization through the next phase of the company's evolution."

    In connection with Dr. Ingelsson joining Wave, he received a share option to purchase 350,000 ordinary shares of Wave and 12,000 restricted share units (RSU). The equity grants were approved by Wave's Compensation Committee and were granted to Dr. Ingelsson on May 8, 2024, outside of the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended, as an inducement material to Dr. Ingelsson's commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $5.85 per share, the closing price on the grant date, and vests over four years with 25% vesting on May 8, 2025, and the remainder vesting in equal quarterly installments over the following three years. The RSU vests as to 100% of the shares on the first anniversary of the grant date.

    About Wave Life Sciences

    Wave Life Sciences (NASDAQ:WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.  

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Dr. Ingelsson's leadership and expertise in genetics and drug discovery and how these capabilities may benefit Wave; beliefs that Dr. Ingelsson's experience will accelerate identification of new genetic insights and the translation of those insights into RNA medicines; the anticipated timing and expectations for delivering data from our clinical trials; and the potential of our RNA medicines platform, and any benefits that may arise as a result thereof. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled "Risk Factors" in Wave's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    Investor Contact:

    Kate Rausch

    +1 617-949-4827

    [email protected]

    Media Contact:

    Alicia Suter

    +1 617-949-4817

    [email protected]



    Primary Logo

    Get the next $WVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    5/15/2024$11.00Overweight
    Wells Fargo
    More analyst ratings

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/21/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:05:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Verdine Gregory L. exercised 266,402 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 577% to 312,517 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 4:30:35 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 9:34:18 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

      SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      10/1/24 5:47:15 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Leadership Updates

    Live Leadership Updates

    See more
    • Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

      CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

      5/9/24 7:00:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

      BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

      3/21/22 7:05:00 AM ET
      $ATHA
      $WVE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

      CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl

      12/2/20 8:00:00 AM ET
      $SNY
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:13:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Wave Life Sciences with a new price target

      Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00

      4/8/25 9:33:34 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Wave Life Sciences with a new price target

      Jefferies initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $26.00

      2/25/25 7:15:48 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Wave Life Sciences Ltd.

      10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:45:16 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Wave Life Sciences Ltd.

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:36:06 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Wave Life Sciences Ltd.

      10-K/A - Wave Life Sciences Ltd. (0001631574) (Filer)

      4/29/25 5:00:21 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      10/1/24 5:54:39 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/30/24 4:39:08 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

      4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/17/24 7:06:57 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $WVE
    Financials

    Live finance-specific insights

    See more

    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care